Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 11, 2024

The Epidemiology Associated With Chronic Spontaneous Urticaria 

Author(s)Brian Keegan, MD, PhD, Giselle Mosnaim, MD, Stanley Goldstein, MD

Giselle Mosnaim, MD, discusses the epidemiology that is associated with CSU.

Episodes in this series

A panel of 4 experts on chronic spontaneous urticaria

EP. 1 The Pathophysiology of Chronic Spontaneous Urticaria

A panel of 4 experts on chronic spontaneous urticaria

EP. 2 Hallmark Symptoms of Chronic Spontaneous Urticaria

A panel of 4 experts on chronic spontaneous urticaria

EP. 3 The Epidemiology Associated With Chronic Spontaneous Urticaria 

A panel of 4 experts on chronic spontaneous urticaria

EP. 4 Differential Diagnosis When Considering Chronic Spontaneous Urticaria 

A panel of 4 experts on chronic spontaneous urticaria

EP. 5 Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria 

A panel of 4 experts on chronic spontaneous urticaria

EP. 6 Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria 

A panel of 4 experts on chronic spontaneous urticaria

EP. 7 Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria 

A panel of 4 experts on chronic spontaneous urticaria

EP. 8 The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment

A panel of 4 experts on chronic spontaneous urticaria

EP. 9 Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

A panel of 4 experts on chronic spontaneous urticaria

EP. 10 Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

A panel of 4 experts on chronic spontaneous urticaria

EP. 11 The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment

A panel of 4 experts on chronic spontaneous urticaria

EP. 12 Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment

A panel of 4 experts on chronic spontaneous urticaria

EP. 13 Patient Education, Provider Education, and Overall Final Thoughts

Video content above is prompted by the following question(s):

Discuss the epidemiology that is associated with chronic spontaneous urticaria, and why this disease might be underdiagnosed.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Clinicians Confront Fragmented Care and the Silent Burden of Undertreated Atopic Dermatitis

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis